Effects of different supplements on Hashimoto's thyroiditis: a systematic review and network meta-analysis

source extracted confidence: high 2026-04-09
#humans #autoantibodies #dietary-supplements #hashimoto-disease #inositol

Effects of different supplements on Hashimoto's thyroiditis: a systematic review and network meta-analysis

Peng et al., 2024 | Front Endocrinol (Lausanne) | Systematic Review

Citation

Peng Bingcong, Wang Weiwei, ... Shan Zhongyan. Effects of different supplements on Hashimoto's thyroiditis: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2024;15:1445878. doi:10.3389/fendo.2024.1445878

Abstract

Clinicians often consider the use of dietary supplements to assist in lowering thyroid autoantibody titres in patients with Hashimoto's thyroiditis (HT). Currently, different supplements differ in their ability to reduce autoantibody levels. The purpose of this article is to compare the ability of different supplements to lower autoantibody titres and restore TSH levels through a systematic literature review. We obtained information from the PubMed, Web of Science, Embase, and Cochrane databases, as well as the China National Knowledge Infrastructure (CNKI). Selected studies included those using selenium, Vitamin D, Myo-inositol, and Myo-inositol in combination with selenium for the treatment of HT patients with euthyroidism. These data were combined using standardised mean differences (SMDs) and assessed using a random effects model. A total of 10 quantitative meta-analyses of case-control studies were selected for this meta-analysis. Compared to the placebo group, the use of selenium supplements was able to significantly reduce the levels of thyroid peroxidase autoantibodies (TPOAb) (SMD: -2.44, 95% CI: -4.19, -0.69) and thyroglobulin autoantibodies (TgAb) (SMD: -2.76, 95% CI: -4.50, -1.02). During a 6-month treatment, the use of Myo-inositol, Vitamin D alone, and the combination of selenium, and Myo-inositol did not effectively reduce TPOAb (Myo-inositol: SMD:-1.94, 95% CI: -6.75, 2.87; Vitamin D: SMD: -2.54, 95% CI: -6.51,1.42; Se+Myo-inositol: SMD: -3.01, 95% CI: -8.96,2.93) or TgAb (Myo-inositol: SMD:-2.02, 95% CI: -6.52, 2.48; Vitamin D: SMD: -2.73, 95% CI: -6.44,0.98; Se+Myo-inositol: SMD: -3.64, 95% CI: -9.20,1.92) levels. Therefore, we recommend that patients with HT(Hashimoto's Thyroiditis) be given an appropriate amount of selenium as an auxiliary treatment during standard-of-care treatment.

Key Findings

Therefore, we recommend that patients with HT(Hashimoto's Thyroiditis) be given an appropriate amount of selenium as an auxiliary treatment during standard-of-care treatment.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population hashimoto
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Autoantibodies
  • Dietary Supplements
  • Hashimoto Disease
  • Inositol
  • Iodide Peroxidase
  • Selenium
  • Vitamin D

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Systematic Review, Journal Article, Network Meta-Analysis
  • Vertical: selenium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09